US 11,992,525 B2
Chimeric influenza vaccines
Chi-Huey Wong, Taipei (TW); Hsin-Yu Liao, New Taipei (TW); Shih-Chi Wang, New Taipei (TW); Yi-An Ko, Taipei (TW); Kuo-I Lin, Taipei (TW); Che Ma, New Taipei (TW); and Ting-Jen Cheng, New Taipei (TW)
Assigned to ACADEMIA SINICA, Taipei (TW)
Filed by ACADEMIA SINICA, Taipei (TW)
Filed on Nov. 3, 2023, as Appl. No. 18/501,578.
Application 18/501,578 is a continuation of application No. 17/998,208, previously published as PCT/US2021/031406, filed on May 7, 2021.
Claims priority of provisional application 63/022,328, filed on May 8, 2020.
Prior Publication US 2024/0100147 A1, Mar. 28, 2024
Int. Cl. A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); A61P 31/16 (2006.01); C07K 14/005 (2006.01)
CPC A61K 39/145 (2013.01) [A61P 31/16 (2018.01); C07K 14/005 (2013.01); A61K 2039/575 (2013.01)] 21 Claims
 
1. An immunogenic composition comprising a monoglycosylated chimeric influenza virus hemagglutinin (HA) polypeptide and an adjuvant;
wherein the monoglycosylated chimeric influenza virus HA polypeptide comprising an amino acid sequence of SEQ ID NO: 4;
wherein the monoglycosylated chimeric influenza virus HA polypeptide has only N-Acetylglucosamine (GlcNAc) at N28, N40, N182, N292, and N497; and
wherein the adjuvant is selected from the group consisting of Al(OH)3, AlPO4, an analog of α-galactosylceramide (α-GalCer), squalene and QS21.